Gilead Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. 

CEO
Daniel P. O'Day
CEODaniel P. O'Day
Employees
17,000
Employees17,000
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1987
Founded1987
Employees
17,000
Employees17,000

GILD Key Statistics

Market cap
155.89B
Market cap155.89B
Price-Earnings ratio
17.13
Price-Earnings ratio17.13
Dividend yield
2.53%
Dividend yield2.53%
Average volume
9.22M
Average volume9.22M
High today
$127.33
High today$127.33
Low today
$124.29
Low today$124.29
Open price
$125.90
Open price$125.90
Volume
5.22M
Volume5.22M
52 Week high
$157.29
52 Week high$157.29
52 Week low
$104.46
52 Week low$104.46

Stock Snapshot

Gilead Sciences(GILD) stock is priced at $125.75, giving the company a market capitalization of 155.89B. It carries a P/E multiple of 17.13 and pays a dividend yield of 2.5%.

During the trading session on 2026-06-12, Gilead Sciences(GILD) shares reached a daily high of $127.33 and a low of $124.29. At a current price of $125.75, the stock is +1.2% higher than the low and still -1.2% under the high.

Trading activity shows a volume of 5.22M, compared to an average daily volume of 9.22M.

The stock's 52-week range extends from a low of $104.46 to a high of $157.29.

The stock's 52-week range extends from a low of $104.46 to a high of $157.29.

GILD News

TipRanks 10h
Gilead Advances Denikitug Trial in Tough-to-Treat Colorectal Cancer

Gilead Sciences (GILD) announced an update on their ongoing clinical study. Gilead Sciences has launched a Phase 2 study titled “A Phase 2, Open Label, Multice...

TipRanks 14h
Gilead announces donation of over 2,000 vials of remdesivir to Uganda

Gilead (GILD) Sciences announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support resp...

Simply Wall St 1d
How Investors Are Reacting To Gilead Sciences New HIV Regimen and Liver Disease Milestones

Gilead Sciences and Merck recently reported that their Phase 3 ISLEND-1 and ISLEND-2 trials for a once-weekly oral HIV regimen met primary efficacy and safety g...

How Investors Are Reacting To Gilead Sciences New HIV Regimen and Liver Disease Milestones

Analyst ratings

80%

of 30 ratings
Buy
80%
Hold
20%
Sell
0%

More GILD News

Benzinga 3d
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial

While the combo showed a numerical improvement in progression-free survival, it did not reach statistical significance, and investigators said the probability o...

Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial
TipRanks 4d
Merck, Gilead announce discontinuation of Phase 3 KEYNOTE-D46/EVOKE-03 study

Merck (MRK) and Gilead Sciences (GILD) announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead’s Trodelvy in combination wi...

Simply Wall St 6d
Gilead Expands Into Autoimmune Orphan Diseases With Ouro Medicines Deal

Gilead Sciences (NasdaqGS:GILD) has closed the acquisition of Ouro Medicines, bringing a clinical-stage BCMAxCD3 T cell engager, gamgertamig, into its pipeline....

Gilead Expands Into Autoimmune Orphan Diseases With Ouro Medicines Deal

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.